A Phase 2 interventional study of EDP-305 1 mg and EDP-305 2.5 mg in Primary Biliary Cholangitis, sponsored by Enanta Pharmaceuticals, Inc. Completed at 86 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-18.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 17 under way, 7 of them phase 3. Liver Cirrhosis, Biliary · United States.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 25th largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 42nd registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
Ipsen · Sites in United States
Women only
Zydus Therapeutics Inc. · Sites in United States
Ages 18+
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 18 · Phase 4 3
First in 1994; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 46 across the 65 interventional studies, 430 across the 17 observational. Of the 62 that completed or were terminated, 33 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Enanta Pharmaceuticals, Inc has 1 study filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis, Biliary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06427395Phase 3Zydus Therapeutics Inc.Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | 2027-04-18 |
| NCT06825559Zydus Therapeutics Inc.Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | 2026-12-31 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07631442Stanford UniversityUsing Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC) | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female with a diagnosis of PBC by at least two of the following criteria:
Exclusion Criteria:
Laboratory Screening Results:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: EDP-305 1 mg
Subjects will take 2 tablets once a day orally for 12 weeks
Drug: EDP-305 2.5 mg
Subjects will take two tablets once a day orally for 12 weeks
Drug: Placebo
Two tablets daily for 12 weeks
Two tablets daily for 12 weeks
Two tablets daily for 12 weeks
Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline
Percent change was calculated as \[(ALP at Week 12 - ALP at Baseline)/ALP at Baseline\] \*100. The participant was considered to have successfully achieved a 20% reduction in ALP if the result was ≤-20. The participant was considered to have successfully achieved ALP normalization if ALP was abnormal at Baseline and normal at Week 12.
Time frame: Baseline and Week 12
Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period
An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.
Time frame: Up to approximately Week 12
Percentage of Participants With a Treatment-Emergent Serious Adverse Event (SAE) During On-Treatment Period
A SAE is any untoward medical occurrence at any dose that results in death, is a life-threatening event, requires inpatient hospitalization or prolonged hospitalization of an existing hospitalization, results in permanent or prolonged disability or incapacity, is a congenital anomaly or birth defect in the offspring of a study subjects, or is a medically important event.
Time frame: Up to approximately Week 12
Percentage of Participants Who Stopped Study Treatment Due to a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period
An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.
Time frame: Up to approximately Week 12
Change From Baseline to Week 12 in Total, Conjugated and Unconjugated Bilirubin
The data presented below was measured using least square mean change from baseline.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT)
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Enhanced Liver Fibrosis (ELF) Panel and N-terminal Type III Collagen Propeptide (PRO C3)
The ELF panel included hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP 1). This endpoint also presents PRO C3 results.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: AST to Platelet Ratio Index (APRI) Score
APRI was calculated as (\[AST level/AST upper limit of normal\]/\[Platelet count 1\^09/L\])×100. AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess liver fibrosis in participants with chronic liver disease. Scores range from 0 to ≥ 2.0, with scores \< 0.5 predictive of no liver fibrosis; scores \>1.5 significant fibrosis; and scores \> 2.0 indicative of cirrhosis. A negative change from baseline indicates a decrease in fibrosis.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Fibrosis-4 (FIB-4) Score
Fibrosis-4 is the ratio of age in years and aminotransferase to platelet count. It is a non-invasive hepatic fibrosis index score that is calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \< 1.45 indicates no or moderate fibrosis and an index of \> 3.25 indicates extensive fibrosis/cirrhosis. A positive change from Baseline indicates increased fibrosis.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Fibrinogen and C Reactive Protein (CRP) Levels
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Interleukin (IL) and Tumor Necrosis Factor (TNF) Levels
For IL, both IL6 and IL1β variants were analysed. For TNF, both TNF α and TNF β (also known as lymphotoxin alpha) variants were analyzed.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Haptoglobin and Alpha2 Macroglobulin Levels
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Triglycerides (TG), Total Cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C)
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Domain and Total Scores on the 5D-Itch Scale
The 5D-Itch scale is a multidimensional questionnaire completed by participants to quantify the magnitude of pruritus, assessed considering the past 2 weeks. Scale range is 1 to 5 covering five dimensions: duration (1=Less than 6 hrs/day to 5=All day), degree (1=Not present to 5=Unbearable), direction (1=Completely resolved to 5=Getting worse), disability (for Sleep rated as 1=Never affects sleep to 5=Delays falling asleep and frequently wakes me up at night; for Leisure/Social, Housework/Errands and Work/School rated as 1=Never affects activity to 5=Always affects activity), and distribution (assess if itching is present in 16 body locations, scored as 1=present at 0-2 locations to 5=present at 14-16 locations). Total scores (including highest disability score obtained from any of the daily activities) ranged between 5 and 25 where higher scores indicated more severe itching. Negative change scores indicate improvement from the baseline score.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in Visual Analog Score (VAS) for Itching
An itch VAS (0-100mm) was used to record the intensity of the event. Participants drew a line on a scale corresponding to the maximum intensity of itch. Lines drawn towards the right of the line indicated greater itching and higher scores indicated more severe itching. Negative change from baseline indicates decrease in itching.
Time frame: Baseline to Week 12
Change From Baseline to Week 12 in Domain Scores on the Primary Biliary Cholangitis-40 (PBC-40) Quality of Life (QoL) Assessment
The PBC-40 is a survey measuring health related quality of life in participants with PBC. The 40 questions from the PBC-40 questionnaire are scored from 1-5, with 5 representing the highest impact and 1 the lowest impact of PBC on the quality of life. Six domains were computed from the 40 questions: symptoms (score range 7-35), itch (0-15), fatigue (11-55), cognition (6-30), social (8-50) and emotional (1-15). Higher scores indicate worse quality of life and negative change scores indicate improvement from the baseline score.
Time frame: Baseline and Week 12
Maximum Plasma Concentration (Cmax) of EDP-305 and Its Metabolites
Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.
Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of EDP-305 and Its Metabolites
Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.
Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of EDP-305 and Its Metabolites
Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.
Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
Percentage Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA) Concentrations
FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.
Time frame: Baseline and Week 12
Percentage Change From Baseline to Week 12 in AUC0-8 and AUC2-8 of Fibroblast Growth Factor 19 (FGF19), 7α-OH-4-cholesten-3-one (C4) and Bile Acid (BA)
AUC0-8 is area under the biomarker concentration-time curve from time zero to 8 hours. AUC2-8 is area under the biomarker concentration-time curve from 2 hours to 8 hours. FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.
Time frame: Day 1 and Week 12: Pre-dose and 2, 6 and 8 hours post-dose
The trial included 68 participants from 43 sites in Australia, Canada, Europe and the United States from December 2017 to January 2020.
| Milestone | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Started | 31 | 28 | 9 |
| Completed | 28 | 22 | 9 |
| Not completed | 3 | 6 | 0 |
| Withdrew: Adverse event | 0 | 5 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Did not meet all inclusion criteria | 1 | 0 | 0 |
Percent change was calculated as \[(ALP at Week 12 - ALP at Baseline)/ALP at Baseline\] \*100. The participant was considered to have successfully achieved a 20% reduction in ALP if the result was ≤-20. The participant was considered to have successfully achieved ALP normalization if ALP was abnormal at Baseline and normal at Week 12.
| percentage of participants | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline | 45.2 | 46.4 | 11.1 |
An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.
| Percentage of participants | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period | 71.0 | 89.3 | 88.9 |
A SAE is any untoward medical occurrence at any dose that results in death, is a life-threatening event, requires inpatient hospitalization or prolonged hospitalization of an existing hospitalization, results in permanent or prolonged disability or incapacity, is a congenital anomaly or birth defect in the offspring of a study subjects, or is a medically important event.
| Percentage of participants | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With a Treatment-Emergent Serious Adverse Event (SAE) During On-Treatment Period | 3.2 | 7.1 | 0 |
An adverse event (AE) was defined as any event, side effect, or untoward medical occurrence in a subject enrolled in a clinical trial whether or not it is considered to have a causal relationship to the study drug. A TEAE was an AE that first occurred or began previous to and worsened on or after the first dose date and before the last dose date +7 days.
| Percentage of participants | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Stopped Study Treatment Due to a Treatment-Emergent Adverse Event (TEAE) During On-Treatment Period | 3.2 | 17.9 | 0 |
The data presented below was measured using least square mean change from baseline.
| μmol/L | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Total | -0.04 (-0.93 to 0.86) | -0.31 (-1.35 to 0.74) | -0.50 (-2.13 to 1.12) |
| Conjugated | -0.55 (-1.03 to -0.06) | -0.51 (-1.08 to 0.06) | 0.13 (-0.75 to 1.00) |
| Unconjugated | 0.71 (-0.02 to 1.44) | 0.22 (-0.61 to 1.06) | -0.50 (-1.81 to 0.81) |
| U/L | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| ALT | -17.35 (-24.45 to -10.25) | -13.14 (-21.58 to 4.71) | 8.20 (-4.61 to 21.02) |
| AST | -12.08 (-17.49 to -6.68) | -11.51 (-17.91 to -5.10) | 9.33 (-0.43 to 19.09) |
| GGT | -95.91 (-114.12 to -77.70) | -124.55 (-146.00 to -103.11) | -9.42 (-42.19 to 23.35) |
The ELF panel included hyaluronic acid (HA), procollagen III amino terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP 1). This endpoint also presents PRO C3 results.
| μg/L | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| HA | 1.17 (-16.69 to 19.03) | -1.16 (-22.20 to 19.87) | 27.83 (-4.20 to 59.86) |
| PIIINP | -0.08 (-1.28 to 1.11) | -0.77 (-2.20 to 0.65) | 3.01 (0.72 to 5.30) |
| TIMP 1 | -16.29 (-32.31 to -0.27) | -20.90 (-39.58 to -2.22) | 25.66 (-3.64 to 54.97) |
| PRO C3 | -0.67 (-4.97 to 3.63) | 2.33 (-2.31 to 6.96) | 9.06 (2.16 to 15.95) |
APRI was calculated as (\[AST level/AST upper limit of normal\]/\[Platelet count 1\^09/L\])×100. AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess liver fibrosis in participants with chronic liver disease. Scores range from 0 to ≥ 2.0, with scores \< 0.5 predictive of no liver fibrosis; scores \>1.5 significant fibrosis; and scores \> 2.0 indicative of cirrhosis. A negative change from baseline indicates a decrease in fibrosis.
| Index | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: AST to Platelet Ratio Index (APRI) Score | -0.16 (-0.25 to 0.06) | -0.12 (-0.23 to 0.01) | 0.22 (0.05 to 0.38) |
Fibrosis-4 is the ratio of age in years and aminotransferase to platelet count. It is a non-invasive hepatic fibrosis index score that is calculated using formula: FIB-4 = (Age \[years\] x AST \[U/L\]) / (platelets \[10\^9/L\] x (square root of ALT \[U/L\])). A FIB-4 index of \< 1.45 indicates no or moderate fibrosis and an index of \> 3.25 indicates extensive fibrosis/cirrhosis. A positive change from Baseline indicates increased fibrosis.
| Index | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Week 12 in Noninvasive Liver Fibrosis Markers: Fibrosis-4 (FIB-4) Score | -0.14 (-0.29 to 0.01) | -0.05 (-0.22 to 0.11) | 0.21 (-0.06 to 0.47) |
| mg/dL | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Fibrinogen | 16.28 (-5.39 to 37.95) | 41.25 (15.56 to 66.93) | 9.47 (-28.82 to 47.76) |
| CRP | -0.57 (-1.62 to 0.49) | -2.69 (-3.89 to -1.50) | 0.41 (-1.53 to 2.34) |
For IL, both IL6 and IL1β variants were analysed. For TNF, both TNF α and TNF β (also known as lymphotoxin alpha) variants were analyzed.
| ng/L | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| IL6 | 0.73 (-0.97 to 2.43) | -2.10 (-4.03 to -0.17) | 0.39 (-2.57 to 3.34) |
| IL1β | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| TNF α | -0.15 (-0.38 to 0.09) | -0.01 (-0.28 to 0.25) | 0.39 (-0.03 to 0.81) |
| TNF β | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| g/L | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Haptoglobin | -0.14 (-0.27 to -0.01) | -0.18 (-0.33 to -0.03) | -0.15 (-0.38 to 0.08) |
| Alpha2 Macroglobulin | -0.02 (-0.09 to 0.05) | -0.00 (-0.08 to 0.08) | 0.02 (-0.11 to 0.15) |
| mmol/L | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| TG | -0.13 (-0.25 to -0.00) | 0.01 (-0.13 to 0.16) | 0.05 (-0.17 to 0.27) |
| TC | -0.47 (-0.80 to -0.14) | -0.46 (-0.85 to -0.08) | 0.17 (-0.42 to 0.76) |
| HDL-C | -0.16 (-0.31 to -0.02) | -0.46 (-0.62 to -0.30) | -0.24 (-0.49 to 0.01) |
| LDL-C | -0.21 (-0.47 to 0.05) | -0.01 (-0.31 to 0.29) | 0.29 (-0.19 to 0.76) |
The 5D-Itch scale is a multidimensional questionnaire completed by participants to quantify the magnitude of pruritus, assessed considering the past 2 weeks. Scale range is 1 to 5 covering five dimensions: duration (1=Less than 6 hrs/day to 5=All day), degree (1=Not present to 5=Unbearable), direction (1=Completely resolved to 5=Getting worse), disability (for Sleep rated as 1=Never affects sleep to 5=Delays falling asleep and frequently wakes me up at night; for Leisure/Social, Housework/Errands and Work/School rated as 1=Never affects activity to 5=Always affects activity), and distribution (assess if itching is present in 16 body locations, scored as 1=present at 0-2 locations to 5=present at 14-16 locations). Total scores (including highest disability score obtained from any of the daily activities) ranged between 5 and 25 where higher scores indicated more severe itching. Negative change scores indicate improvement from the baseline score.
| Scores on a scale | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Duration | 0.01 (-0.27 to 0.29) | 0.41 (0.11 to 0.71) | -0.24 (-0.73 to 0.25) |
| Degree | 0.00 (-0.25 to 0.26) | 0.65 (0.37 to 0.93) | -0.53 (-0.96 to 0.10) |
| Direction | -0.63 (-1.12 to -0.15) | 0.36 (-0.17 to 0.90) | -0.65 (-1.46 to 0.16) |
| Disability | -0.24 (-0.63 to 0.15) | 0.85 (0.42 to 1.28) | -0.61 (-1.28 to 0.05) |
| Distribution | 0.07 (-0.32 to 0.45) | 0.81 (0.38 to 1.24) | -0.42 (-1.08 to 0.24) |
| Total | -0.95 (-2.29 to 0.39) | 3.19 (1.74 to 4.64) | -3.16 (-5.50 to -0.82) |
An itch VAS (0-100mm) was used to record the intensity of the event. Participants drew a line on a scale corresponding to the maximum intensity of itch. Lines drawn towards the right of the line indicated greater itching and higher scores indicated more severe itching. Negative change from baseline indicates decrease in itching.
| Scores on a scale | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline to Week 12 in Visual Analog Score (VAS) for Itching | 0.55 (-8.35 to 9.44) | 13.64 (4.00 to 23.29) | -11.93 (-27.05 to 3.18) |
The PBC-40 is a survey measuring health related quality of life in participants with PBC. The 40 questions from the PBC-40 questionnaire are scored from 1-5, with 5 representing the highest impact and 1 the lowest impact of PBC on the quality of life. Six domains were computed from the 40 questions: symptoms (score range 7-35), itch (0-15), fatigue (11-55), cognition (6-30), social (8-50) and emotional (1-15). Higher scores indicate worse quality of life and negative change scores indicate improvement from the baseline score.
| Scores on a scale | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| Symptoms | -0.21 (-1.47 to 1.06) | -1.46 (-2.93 to 0.00) | -0.06 (-2.30 to 2.18) |
| Itch | 0.18 (-0.72 to 1.09) | 1.74 (0.69 to 2.78) | -1.73 (-3.33 to -0.13) |
| Fatigue | -0.36 (-2.58 to 1.86) | -0.22 (-2.79 to 2.34) | 0.10 (-3.82 to 4.01) |
| Cognition | -0.21 (-1.46 to 1.04) | 0.82 (-0.63 to 2.27) | -0.48 (-2.66 to 1.71) |
| Social | -0.38 (-2.22 to 1.46) | 0.96 (-1.17 to 3.08) | 1.73 (-1.52 to 4.99) |
| Emotional | -0.77 (-1.54 to 0.01) | 0.23 (-0.68 to 1.13) | -0.15 (-1.52 to 1.22) |
Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.
| ng/mL | EDP-305 1 mg - Pharmacokinetic Substudy | EDP-305 2.5 mg - Pharmacokinetic Substudy |
|---|---|---|
| EDP-305 Day 1 | 15.4 ± 44.30 | 27.9 ± 54.19 |
| EDP-305 Week 12 | 10.8 ± 67.77 | 50.4 ± 53.20 |
| EP-022571 Day 1 | 0.5 ± 44.58 | 0.6 ± 61.81 |
| EP-022571 Week 12 | 0.2 ± 59.57 | 1.3 ± 160.28 |
| EP-022572 Day 1 | 0.5 ± 41.69 | 0.8 ± 38.27 |
| EP-022572 Week 12 | 0.2 ± 41.74 | 1.6 ± 138.55 |
| EP-022679 Day 1 | 0.8 ± 113.24 | 1.7 ± 115.17 |
| EP-022679 Week 12 | 0.6 ± 147.81 | 10.9 ± 352.53 |
Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.
| hours | EDP-305 1 mg - Pharmacokinetic Substudy | EDP-305 2.5 mg - Pharmacokinetic Substudy |
|---|---|---|
| EDP-305 Day 1 | 6.00 (2.02 to 6.03) | 6.02 (2.00 to 8.00) |
| EDP-305 Week 12 | 7.01 (6.00 to 8.02) | 6.01 (2.05 to 8.02) |
| EP-022571 Day 1 | 2.00 (2.00 to 6.00) | 6.00 (2.00 to 6.10) |
| EP-022571 Week 12 | 6.00 (2.00 to 6.00) | 4.00 (2.00 to 6.10) |
| EP-022572 Day 1 | 2.00 (2.00 to 8.00) | 6.00 (2.00 to 6.10) |
| EP-022572 Week 12 | 6.00 (6.00 to 8.00) | 4.00 (2.00 to 6.00) |
| EP-022679 Day 1 | 6.00 (6.00 to 8.00) | 6.10 (2.00 to 8.00) |
| EP-022679 Week 12 | 6.00 (6.00 to 8.00) | 6.00 (6.00 to 8.00) |
Metabolites of EDP-305 are EP-022571, EP-022572, and EP-022679.
| h*ng/mL | EDP-305 1 mg - Pharmacokinetic Substudy | EDP-305 2.5 mg - Pharmacokinetic Substudy |
|---|---|---|
| EDP-305 Day 1 | 85.50 ± 51.57 | 95.30 ± 141.72 |
| EDP-305 Week 12 | 67.60 ± 75.47 | 316.20 ± 42.34 |
| EP-022571 Day 1 | 2.30 ± 37.32 | 2.00 ± 132.47 |
| EP-022571 Week 12 | 0.90 ± 78.75 | 7.30 ± 154.62 |
| EP-022572 Day 1 | 2.50 ± 32.37 | 2.90 ± 96.70 |
| EP-022572 Week 12 | 1.20 ± 53.12 | 10.10 ± 148.55 |
| EP-022679 Day 1 | 3.70 ± 109.30 | 5.00 ± 305.62 |
| EP-022679 Week 12 | 3.00 ± 203.04 | 57.00 ± 343.47 |
FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.
| Percentage change from baseline | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| FGF19 | 28.10 ± 94.526 | 46.90 ± 76.667 | 39.83 ± 100.579 |
| C4 | -18.066 ± 114.9959 | -61.960 ± 42.8603 | 39.839 ± 163.6265 |
| BA | -21.79 ± 74.581 | -15.79 ± 112.934 | 3.17 ± 48.656 |
AUC0-8 is area under the biomarker concentration-time curve from time zero to 8 hours. AUC2-8 is area under the biomarker concentration-time curve from 2 hours to 8 hours. FGF19 was measured in plasma. BA was measured in serum. C4 was measured in serum.
| Percentage change from baseline | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| FGF19 AUC0-8 | 24.9 ± 68.90 | 25.0 ± 71.72 | -25.9 ± NA |
| FGF19 AUC 2-8 | 7.8 ± 86.25 | 18.9 ± 66.35 | -25.3 ± NA |
| C4 AUC0-8 | 3.7 ± 51.74 | 100.0 ± NA | 138.2 ± NA |
| C4 AUC2-8 | -9.2 ± 66.30 | -100.0 ± NA | 122.5 ± NA |
| BA AUC0-8 | -20.7 ± 74.80 | -51.5 ± 41.06 | -26.1 ± NA |
| BA AUC2-8 | -33.6 ± 76.26 | -42.8 ± 56.77 | -24.4 ± NA |
Collected over Up to 16 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EDP-305 1 mg | 0/31 (0%) | 1/31 (3.2%) | 23/31 (74.2%) |
| EDP-305 2.5 mg | 0/28 (0%) | 2/28 (7.1%) | 24/28 (85.7%) |
| Placebo | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| Event | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 0/31 | 1/28 | 0/9 |
| FatigueGeneral disorders | 0/31 | 1/28 | 0/9 |
| Abdominal painGastrointestinal disorders | 0/31 | 1/28 | 0/9 |
| PruritisGastrointestinal disorders | 0/31 | 1/28 | 0/9 |
| UrticariaGastrointestinal disorders | 0/31 | 1/28 | 0/9 |
| Escherichia urinary tract infectionInfections and infestations | 0/31 | 1/28 | 0/9 |
| Bacterial infectionInfections and infestations | 1/31 | 0/28 | 0/9 |
| Event | EDP-305 1 mg | EDP-305 2.5 mg | Placebo |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 11/31 | 16/28 | 3/9 |
| HeadacheNervous system disorders | 3/31 | 5/28 | 3/9 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 5/31 | 9/28 | 0/9 |
| Dry mouthGastrointestinal disorders | 0/31 | 1/28 | 2/9 |
| Back painMusculoskeletal and connective tissue disorders | 0/31 | 1/28 | 2/9 |
| Abdominal pain upperGastrointestinal disorders | 4/31 | 1/28 | 0/9 |
| ContusionInjury, poisoning and procedural complications | 0/31 | 0/28 | 1/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/31 | 1/28 | 1/9 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/31 | 0/28 | 1/9 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/31 | 0/28 | 1/9 |
| Age, Continuous(years) | EDP-305 1 mg | EDP-305 2.5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 57.4 ± 8.61 | 54.9 ± 10.92 | 56.9 ± 8.49 | 56.3 ± 9.55 |
| Sex: Female, Male(Participants) | EDP-305 1 mg | EDP-305 2.5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 31 | 27 | 9 | 67 |
| Male | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | EDP-305 1 mg | EDP-305 2.5 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 0 | 5 |
| Not Hispanic or Latino | 27 | 25 | 9 | 61 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | EDP-305 1 mg | EDP-305 2.5 mg | Placebo | Total |
|---|---|---|---|---|
| White | 28 | 27 | 9 | 64 |
| All other races | 3 | 1 | 0 | 4 |
| Region of Enrollment(participants) | EDP-305 1 mg | EDP-305 2.5 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 16 | 12 | 2 | 30 |
| Canada | 1 | 1 | 1 | 3 |
| Australia | 2 | 1 | 2 | 5 |
| Spain | 3 | 2 | 2 | 7 |
| United Kingdom | 6 | 6 | 1 | 13 |
| Austria | 0 | 2 | 0 | 2 |
| Belgium | 0 | 1 | 0 | 1 |
| France | 0 | 1 | 0 | 1 |
| Germany | 2 | 1 | 1 | 4 |
| Netherlands | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Dec 2019, 23 months.
Results were first posted in May 2021, 1 year 4 months after primary completion. A results delay was requested in Dec 2020.
Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-305